Rozbor firmy
Novo Nordisk (NVO): Company Analysis and Investment Suitability
Key takeaways
- Novo Nordisk is the Danish pioneer of GLP-1 drugs with the Ozempic (diabetes) and Wegovy (obesity) brands.
- After several disappointments (study results, competition from Lilly) the stock fell sharply from its highs.
- Today it trades significantly cheaper than Eli Lilly — P/E ~22 versus ~58.
- The business remains extraordinarily profitable (gross margin ~84%) and pays a decent dividend.
- The key question: can Novo hold its market share against Lilly and new competition, or will growth continue to slow?
Novo Nordisk is the Danish company that actually started the entire obesity drug boom. But then competition caught up, a few setbacks arrived, and the stock fell from its heights. Today it is a fascinating case: the same megatrend as Eli Lilly, but at a fraction of the valuation.
What Novo Nordisk Does
Novo is a pharmaceutical company historically specialized in diabetes. From that expertise grew the blockbusters Ozempic (for diabetes) and Wegovy (for obesity) from the GLP-1 group — drugs that transformed the entire sector and turned weight loss into the pharmaceutical market of the decade.
The Economic Moat
- Decades of experience with diabetes and peptide drugs — deep know-how.
- Patents and brands — Ozempic and Wegovy are globally recognized.
- Manufacturing capacity — the ability to produce injectable drugs at scale is itself a barrier.
- Pipeline — next-generation obesity drugs (including tablets).
Why the Stock Fell
After a rocket-like rise, sobering arrived: some study results disappointed, Eli Lilly offered a more effective drug and began taking share, and cheaper compounded competition also appeared. Revenue growth slowed and the market repriced the stock sharply downward. That is why it is so cheap relative to Lilly today.
Valuation: Quality at a More Reasonable Price
As of June 4, 2026, the ADR trades around $78, market capitalization is approximately $350 billion, and the P/E (TTM) is around 22 (forward ~18). For a company with an 84% gross margin in a growing sector, this is notably lower than rival Lilly — the market is simply pricing in the assumption that Novo will be the second of the pair.
Dividend and Capital Allocation
Novo pays a decent dividend (yield ~1.8%, higher than Lilly's precisely because of the price decline) and buys back shares. It is returning more cash to shareholders than its more expensive rival.
Main Risks
- Competition from Lilly — more effective drugs are taking share; this is the main theme.
- Dependence on GLP-1 — a large part of the business rests on one category.
- Pricing pressure — politicians and insurers are pushing drug prices down.
- Value trap — "cheap" can keep getting cheaper if growth does not stop decelerating.
Investment Thesis
Novo Nordisk is a world-class business on the same megatrend as Eli Lilly, but after the price fall available at a significantly more reasonable valuation. It is the classic choice between quality at a premium (Lilly) and quality at a discount with a question mark (Novo). For an investor who does not want to decide which of the two will win, the cleanest approach is to hold both through a healthcare ETF (XDWH).
FAQ
Why is Novo Nordisk cheaper than Eli Lilly?
Because Novo's growth has slowed, some studies disappointed, and Lilly is taking share with a more effective drug. The market therefore prices in the assumption that Novo will be the second of the pair and values it lower.
Are Ozempic and Wegovy the same thing?
They have the same active ingredient (semaglutide), but Ozempic is registered for diabetes and Wegovy for obesity (at a different dosage).
Is Novo Nordisk a cheap opportunity or a value trap?
That is the core of the thesis. Either the market has excessively punished a quality company, or Novo is permanently losing its lead to Lilly. The answer depends on the trajectory of its market share and pipeline.
In which of your ETFs can I find Novo Nordisk?
In the healthcare fund XDWH.